Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242748 · ClinicalTrials.gov registry record · Phase 3
A Degarelix Trial in Patients With Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
NCT01242748 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 288 participants.
The verdict
NCT01242748, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
Study Summary
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
Interventions
- DRUG Degarelix
- DRUG Goserelin acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242748
The ClinicalTrials.gov registry entry for NCT01242748 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT01242748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01242748 about?
NCT01242748 is a clinical study titled "A Degarelix Trial in Patients With Prostate Cancer". A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
What is the current status of trial NCT01242748?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2010-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01242748?
The interventions under investigation include: Degarelix (DRUG), Goserelin acetate (DRUG).
Who is sponsoring clinical trial NCT01242748?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.